Albiglutide vs Dulaglutide
How they differ
- FDA status. Albiglutide: FDA-approved as Tanzeum; discontinued.1 Dulaglutide: FDA-approved as Trulicity.2,3
Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.
Side by side
| Topic | Albiglutide | Dulaglutide |
|---|---|---|
| What it is | A GLP-1 receptor agonist fusion protein, in which GLP-1 analogue peptides are fused to human albumin, recorded by FDA’s substance registry as albiglutide.4 | A GLP-1 receptor agonist. The label states that dulaglutide has 90% amino acid sequence similarity to human GLP-1.2 |
| FDA status | FDA-approved FDA-approved as Tanzeum; discontinued1 FDA-approved, but discontinued. Drugs@FDA lists Tanzeum, application 125431, with an original approval date of April 15, 2014, and lists it as discontinued.1 | FDA-approved FDA-approved. Drugs@FDA lists Trulicity with an original approval date of September 18, 2014. The label carries a boxed warning about thyroid C-cell tumors in rats.2,3 |
| HHS compounding policy, October 30, 2026 | Not among the six peptides the policy lists.5 HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Albiglutide is not among them.5,6 | Not among the six peptides the policy lists.5 |
| FDA compounding safety-risk page | Not listed. FDA’s compounding safety-risk page, current as of April 22, 2026, does not list albiglutide.7 | Not addressed in this profile’s sources. |
| Kinds of studies cited |
|
|
| Records collected | 13 ClinicalTrials.gov records and 4 PubMed records collected | 11 ClinicalTrials.gov records and 38 PubMed records collected |
| Area of study | ||
| Latest dated events |
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Citations
Sources
Numbered markers in the text point here. Each link opens the original public record.
- 1Drugs@FDA: TANZEUM (albiglutide), application 125431 · original approval April 15, 2014 ↗
U.S. Food and Drug Administration · Official source · Source checked November 16, 2026
- 2TRULICITY (dulaglutide) injection, solution · SPL version 62 · published 2026-08-10 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked September 15, 2026
- 3Drugs@FDA application BLA125469 · original submission status AP · 2014-09-18 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 4Albiglutide substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 16, 2026
- 5HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 6Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 7Certain bulk drug substances for use in compounding that may present significant safety risks ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 8Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial (2018) · PMID 30291013 ↗
The Lancet · Official source · Source checked November 16, 2026